My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

59.35 +0.17 (+0.29%)

Streaming Delayed Price Updated: 3:59 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

28 29 Next >

Stock Analysis: Roche Holding AG ↗

May 16, 2023

Roche is a Swiss biopharmaceutical and diagnostic company.

Via Talk Markets

3 Stocks That Are Reshaping the Future ↗

May 16, 2023

As the population ages and AI develops, these three companies stand out among stocks reshaping the future.

Via InvestorPlace

Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗

May 13, 2023

Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....

Via Talk Markets

EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials ↗

May 04, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.

Via Benzinga

Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish ↗

April 28, 2023

Tempest Therapeutics Inc (NASDAQ: TPST) announced

Via Benzinga

Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost? ↗

April 27, 2023

The company reported lighter-than-expected declines due to Keytruda and Gardasil.

Via Investor's Business Daily

Is Roche a Buy Now? ↗

March 20, 2023

Roche focuses on the long-term.

Via The Motley Fool

Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗

April 26, 2023

Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)

Via Benzinga

Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls ↗

April 26, 2023

Both GSK and Roche experienced declining Covid-related sales in the first quarter.

Via Investor's Business Daily

EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial ↗

April 26, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at...

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health ↗

April 25, 2023

The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.

Via Benzinga

Biogen To Report Q1 Earnings: Here's What To Expect ↗

April 21, 2023

We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%.

Via Talk Markets

FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma ↗

April 20, 2023

Via Benzinga

EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗

April 13, 2023

The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...

Via Benzinga

Trillions In Biotech Stock Gains Trace Back To This Financier ↗

April 13, 2023

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Via Investor's Business Daily

Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗

April 11, 2023

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Via The Motley Fool

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies ↗

March 30, 2023

Via Benzinga

Roche's Slow Growth Shouldn't Drive Investors Away ↗

March 28, 2023

New treatments for various cancers, eye diseases, and more may bring in future revenues.

Via The Motley Fool

Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease ↗

March 22, 2023

Via Benzinga

New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗

March 20, 2023

Via Benzinga

Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy ↗

March 17, 2023

Via Benzinga

Daily Stock Analysis: Roche Holding AG ↗

March 16, 2023

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was...

Via Talk Markets

FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗

March 09, 2023

Via Benzinga

The Top 7 Growth Stocks in Biotech ↗

March 03, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Via InvestorPlace

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

Why Sarepta Therapeutics' Shares Rose 23.4% This Week ↗

March 02, 2023

The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.

Via The Motley Fool

3 Best Growth Stocks to Buy In March ↗

March 02, 2023

These three red-hot growth stocks have more room to run.

Via The Motley Fool

Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients ↗

February 27, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.